Catalyst

Slingshot members are tracking this event:

CTI Biopharma's IND for pacritinib has been placed on full clinical hold

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CTIC

100%

Additional Information

Additional Relevant Details
The FDA's February 8, 2016, letter notes the interim overall survival results from PERSIST-2 show a detrimental effect on survival consistent with the results from PERSIST-1. The deaths in PERSIST-2 in pacritinib-treated patients include intracranial hemorrhage, cardiac failure and cardiac arrest. The FDA made recommendations that supersede the recommendations made by the FDA in connection with the partial clinical hold imposed by the FDA on February 4, 2016. The current recommendations include conducting dose exploration studies for pacritinib in patients with myelofibrosis, submitting final study reports and datasets for PERSIST-1 and PERSIST-2, providing certain notifications, revising relevant statements in the related Investigator's Brochure and informed consent documents and making certain modifications to protocols. In addition, the FDA recommended that the Company request a meeting prior to submitting a response to full clinical hold.
http://investors.cti...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 09, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Pacritinib, Clinical Hold, Ind